NEWTOWN | Jotup

NANBAN VENTURES LLC INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation into NANBAN VENTURES LLC and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Retrieved on:

금요일, 10월 20, 2023

Sakthivel, Venture, Complaint, LLP, Hindenburg, Hindenburg Research

Details of the alleged fraud were published in a report by Hindenburg Research entitled, “Nanban Ventures: With ‘Friends’ Like These…,” on October 17, 2023.

Key Points:

Details of the alleged fraud were published in a report by Hindenburg Research entitled, “Nanban Ventures: With ‘Friends’ Like These…,” on October 17, 2023.
If you have information that could assist in the Nanban Investigation or if you are an Nanban investor who suffered a loss and would like to learn more, you can provide your information HERE .
THE WRONGDOING: The individuals, through the “Nanban” companies, raised at least $129.7 million by using allegedly fraudulent securities offerings.
On October 5, 2023, the United States Securities and Exchange Commission filed a Complaint against the above-referenced parties alleging a variety of legal claims.

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Retrieved on:

목요일, 10월 19, 2023

Pharmacology, AACR, Mantle cell lymphoma, Data, CD1, European, Biology, MCL, Cancer, Therapy, BTK, American Association for Cancer Research, Patient, Cyclin D1, Pharmaceutical industry

NEWTOWN, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that one of the Company’s scientific collaborators, Gaël Roué, Ph.D., from the Josep Carreras Leukaemia Research Institute, Spain, made a podium presentation during the European MCL Network Annual Meeting in Dublin, Ireland on October 7, 2023 regarding promising ongoing preclinical studies of narazaciclib, in combination with ibrutinib and other targeted therapies used in the treatment for mantle cell lymphoma.

Key Points:

The biology of MCL is very interesting to Onconova because of the link to cyclin D1 (CD1) overexpression.
We believe this molecular feature could make MCL amenable to treatment combinations that include narazaciclib,” said Steven Fruchtman, M.D., President and CEO of Onconova.
Together, these data provide a foundation of support for using narazaciclib in MCL and other cyclin-dependent indications.
Data from the combination of narazaciclib and ibrutinib showed significant synergistic anti-tumor activity in both sensitive and ibrutinib-resistant MCL models.

Encouraging Rigosertib Data Presented at EADV as Late Breaker

Retrieved on:

목요일, 10월 12, 2023

Professor, Cancer, Journal of the European Academy of Dermatology and Venereology, Late, RDEB, PMU, Carcinoma, Therapy, SCC, Concha bullosa, IST, Patient, Pharmaceutical industry, Dermatology, Venereology

“RDEB-associated SCC is a devastating disease with few if any treatment options for advanced patients.

Key Points:

“RDEB-associated SCC is a devastating disease with few if any treatment options for advanced patients.
We are very pleased for additional data on the potential use of rigosertib in patients with RDEB-associated SCC to be presented as a ‘late breaker’ at EADV 2023,” said Steven Fruchtman, M.D., President and CEO of Onconova.
“We believe that rigosertib’s profile and impact on key cell signaling pathway targets, including PLK-1 kinase, could make rigosertib a very attractive approach for this indication and other cancers.
I am pleased to share the initial encouraging patient experience with rigosertib at this conference.

RTX SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Current Holders of RTX Corporation f/k/a Raytheon Technologies Corporation (NYSE: RTX) to Consult Legal Counsel About the Potential Legal Remedies

Retrieved on:

목요일, 10월 12, 2023

NYSE, Family, LLP, RTX, Reuters, Pratt & Whitney, News, Raytheon Technologies, GTF, Airbus

NEWTOWN, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating potential breach of fiduciary duty claims on behalf of current holders of RTX Corporation f/k/a Raytheon Technologies Corporation (“RTX”) (NYSE: RTX) common stock who acquired their shares between February 8, 2021, and July 25, 2023, inclusive.

Key Points:

NEWTOWN, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating potential breach of fiduciary duty claims on behalf of current holders of RTX Corporation f/k/a Raytheon Technologies Corporation (“RTX”) (NYSE: RTX) common stock who acquired their shares between February 8, 2021, and July 25, 2023, inclusive.
Current holders of RTX stock may pursue corporate governance reforms.
Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .
One of RTX’s principal business segments, Pratt & Whitney, produces the PW1000G Geared Turbofan (“GTF”) engine family, which is currently the subject of shareholder litigation.

Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices

Retrieved on:

목요일, 10월 12, 2023

Management of multiple sclerosis, United, Falling, Gait, Stroke, Letter, Risk, Pons, University, HSDT, Social services, Patient, Pharmaceutical industry, Health

NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it has received a letter of intent (“LOI”) from the Québec Ministry of Health and Social Services (“MSSS”) for the purchase of 30 Portable Neuromodulation Stimulator (“PoNS®”) devices as part of an initiative to assess the value of using PoNS to treat patients suffering symptoms due to stroke.

Key Points:

“Clinical evidence shows that stroke patients treated with PoNS experience significant improvement in gait and balance as well as a reduced risk of falling,” said Dane Andreeff, Helius’ President and Chief Executive Officer.
“We are grateful that a second important Canadian healthcare provider has recognized the potential benefits of PoNS Therapy.
A few weeks ago, the University of Montreal placed an order for ten PoNS devices to be used in a research study assessing stroke recovery, and the MSSS’s initiative will allow 30 more patients to benefit from PoNS Therapy through MSSS’s funding.
We believe this order will accelerate adoption in Canada and, importantly, provide invaluable therapeutic evidence to support Helius’ ongoing efforts to receive authorization for stroke in the United States.”
The sales of these PoNS devices are expected to commence in the fourth quarter of 2023 and extend through the first quarter of 2024.

Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences

Retrieved on:

월요일, 10월 2, 2023

HSDT, Helios, Pharmaceutical industry, Nightclub, Risk management

NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Jeff Mathiesen, Chief Financial Officer, will participate at two upcoming conferences as follows:

Key Points:

NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Jeff Mathiesen, Chief Financial Officer, will participate at two upcoming conferences as follows:
Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact JonesTrading.

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Retrieved on:

목요일, 9월 28, 2023

SCC, Late, Journal of the European Academy of Dermatology and Venereology, RDEB, Cancer, Concha bullosa, Congress, Patient, Therapy, Pharmaceutical industry, Dermatology, Venereology

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.

Key Points:

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

Retrieved on:

목요일, 9월 28, 2023

Management of multiple sclerosis, Helios, CMS, GTIN, Pons, HSDT, UPC, Prescription, Pharmacy, Medicare, PBM, Durable medical equipment, Global Trade Item Number, HCPCS, Wolters Kluwer, GameChanger, Health care

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator (“PoNS®”) system and mouthpiece have been assigned universal product code (“UPC”) numbers by Wolters Kluwer Health – Medi-Span® (“Medi-Span”). Medi-Span is the leading automated clinical screening solution– providing a data backbone and vital support to payers, pharmacy benefit managers (“PBMs”), wholesalers, and manufacturers.

Key Points:

The PoNS system has been assigned the Global Trade Item Number (“GTIN”) of 00864288000462, with a direct price of $25,700.
Consequently, this will allow Helius to pursue reimbursement through both the pharmacy and the Durable Medical Equipment (“DME”)/HCPCS pathways.
“Receiving UPC numbers for the PoNS system and mouthpiece is a gamechanger for Helius,” said Dane Andreeff, Helius’ President and Chief Executive Officer.
"We will now be able to reference these UPC numbers as we negotiate reimbursement with third party payers, and prescriptions can be written with these UPC numbers.

LUMN INVESTOR ALERT: Edelson Lechtzin LLP Urges Lumen Technologies, Inc. (NYSE: LUMN) Shareholders with Substantial Losses to Consult Legal Counsel About the Pending Securities Fraud Class Action

Retrieved on:

금요일, 9월 22, 2023

Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .

Key Points:

Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .
A copy of the class action complaint can be viewed HERE .
Based in Monroe, Louisiana, Lumen Technologies, Inc. provides telecommunications, network services, security, cloud solutions, voice, and managed services.
On this news, Lumen’s stock price fell $0.15 per share, or 8.11%, to close at $1.70 per share on July 17, 2023.

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference

Retrieved on:

목요일, 9월 21, 2023

NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will exhibit at the Academy of Neurologic Physical Therapy 2023 Annual Conference, September 28-30 at the Hyatt Regency Minneapolis, marking its first appearance at the conference.

Key Points:

The Company’s focus at booth 7 will be its innovative Portable Neuromodulation Stimulator (PoNS®), an orally applied therapy delivered by translingual neurostimulation to improve gait deficit in people with multiple sclerosis (“MS”) .
Helius’ debut at the conference is timely, coming just after National Rehabilitation Awareness Week (Sept. 18-24) and on the eve of National Physical Therapy Month (October).
An individualized physical therapy regimen performed with the PoNS device, mostly in clinic for the first two weeks then at home for twelve additional weeks, is the hallmark of PoNS Therapy™.
When used regularly and consistently over the 14-week treatment period, PoNS triggers neuroplastic mechanisms that can lead to significant improvement in gait function .